



Cadila Healthcare Limited

Registered Office : Zydus Tower , Satellite Cross Roads, Ahmedabad - 380015.
Tel. No. (+91-79) 2686 8100 Fax No. : (+91-79) 2686 2365/66 Website : www.zyduscadila.com

Unaudited [Provisional] Consolidated Financial Results for the Quarter ended December 31, 2008.

CONSOLIDATED					Sr. No.	Particulars	COMPANY				
Rupees in Lacs [except for share data]							Rupees in Lacs [except for share data]				
3 Months ended December 31, 2008 [UnAudited]	Corresponding 3 Months period ended in the previous year December 31, 2007 [UnAudited]	9 Months Period ended on December 31, 2008 [UnAudited]	Corresponding 9 Months period ended in the previous year December 31, 2007 [UnAudited]	Previous Accounting Year ended on March 31, 2008 [Audited]			3 Months ended December 31, 2008 [UnAudited]	Corresponding 3 Months period ended in the previous year December 31, 2007 [UnAudited]	9 Months Period ended on December 31, 2008 [UnAudited]	Corresponding 9 Months period ended in the previous year December 31, 2007 [UnAudited]	Previous Accounting Year ended on March 31, 2008 [Audited]
75048	58974	220686	179664	236380	1	Sales & Income from operations :	37804	42755	130134	133786	171914
1421	2825	4701	7749	9777	A	Gross Sales	994	2125	3343	6526	7713
73627	56149	215985	171915	226603	B	Less : Excise Duty	36810	40630	126791	127260	164201
1283	1804	4424	4221	5845	C	Net Sales	6630	3244	18814	6584	9964
74910	57953	220409	176136	232448	D	Other Income from Operations	43440	43874	145605	133844	174165
(3773)	(4060)	(7515)	(4848)	(4552)	E	Total sales and other income from operations	(620)	(1227)	(830)	(638)	330
19572	15536	51359	43456	54060	2	Expenditure :	14895	11607	37761	35675	45374
8618	8167	27608	21911	29520	A	Increase [-] / Decrease [+] in stock in trade & work in progress	748	5527	10808	13777	17431
9606	7111	27711	20622	27656	B	Consumption of materials	5435	4945	17259	14245	19254
2994	2697	8042	7436	9687	C	Purchase of traded goods	2125	1854	5973	5424	7337
26643	20841	75583	60352	79785	D	Employees cost	12340	14584	49113	44274	58568
63660	50292	182788	148929	196156	E	Depreciation & Amortisation	34923	37290	120084	112757	148294
11250	7661	37621	27207	36292	F	Other Expenditure	8517	6584	25521	21087	25871
999	17	1033	50	88	G	Total Expenditure	2432	1518	4494	3187	3988
12249	7678	38654	27257	36380	3	Profit from Operations before Other Income, Interest & Exceptional Items [1 - 2]	10949	8102	30015	24274	29859
2334	1218	4809	3314	4443	4	Other Income	1650	906	3282	2231	3098
1108	(550)	3560	(1560)	(1090)	5	Profit before Interest & Exceptional Items [3 + 4]	625	(548)	1399	(1559)	(1092)
3442	668	8369	1754	3353	6 A	Interest & financial charges	2275	358	4681	672	2006
8807	7010	30285	25503	33027	B	Gain [-] / Loss [+] on Exchange Rate Fluctuations on Foreign Currency Loans	8674	7744	25334	23602	27853
0	(447)	(182)	(687)	(691)	C	Total Financial cost	0	(240)	0	(484)	(484)
8807	6563	30103	24816	32336	7	Profit after Interest but before Exceptional Items [5 - 6]	8674	7504	25334	23118	27369
2835	1776	5076	4121	6126	8	Exceptional Items	1450	1190	3000	3040	3750
5972	4787	25027	20695	26210	9	Profit [+] / Loss [-] from Ordinary Activities before tax [7 + 8]	7224	6314	22334	20078	23619
0	0	0	0	0	10	Tax expense	0	0	0	0	0
5972	4787	25027	20695	26210	11	Net Profit [+] / Loss [-] from Ordinary Activities after tax [9 - 10]	7224	6314	22334	20078	23619
81	369	(519)	(131)	(451)	12	Extraordinary items [net of tax expense]	7224	6314	22334	20078	23619
6053	5156	24508	20564	25759	13	Net Profit [+] / Loss [-] for the period [11 - 12]	6280	6280	6280	6280	6280
6280	6280	6280	6280	6280	14	Adjustments on consolidation	6280	6280	6280	6280	6280
4.43*	4.10	17.95*	16.37	20.51	15	Net Profit [+] / Loss [-] for the period [13 + 14]	6280	6280	6280	6280	6280
4.43*	4.10	17.95*	16.37	20.51	16	Paid-up equity share capital [Face Value Rs. 5 /-]	6280	6280	6280	6280	6280
				99940	17	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year					99100
					18	Earnings Per Share [EPS] [For the period - not Annualised]:					
					A	Basic and diluted EPS before Extraordinary Items [Rs.]	5.29*	5.03	16.36*	15.98	18.80
					B	Basic and diluted EPS after Extraordinary items [Rs.]	5.29*	5.03	16.36*	15.98	18.80
					19	Public shareholding :					
						- Number of shares	35138950	35150458	35138950	35150458	35150458
						- Percentage of Shareholding	27.97%	27.98%	27.97%	27.98%	27.98%

Notes :

- [1] Pursuant to Clause 41 of the Listing Agreement, the company has opted to publish only the consolidated results. Investors can view the standalone results of the company on the company's website: www.zyduscadila.com and/or on the websites of BSE [www.bseindia.com] and / or NSE [www.nseindia.com].
- [2] The above results for the quarter / nine months period ended on December 31, 2008 were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on January 27, 2009 and the Auditors of the Company have carried out limited review of the financial results of the Company for the quarter / nine months period ended December 31, 2008.
- [3]* The Honble High Court of Gujarat has approved the Composite Scheme of Arrangement between Carnation Nutra-Analogue Foods Limited ("Carnation") (now renamed as Zydus Wellness Ltd), Cadila Healthcare Limited ("Cadila") and Zydus Hospitals and Medical Research Private Limited ("ZHMRL") and their respective shareholders and Creditors ("the Scheme") on October 23, 2008. Cadila will issue 1,08,85,305 additional shares pursuant to the scheme. Due to this the results of the quarter and nine months ended on December 31, 2008 are not strictly comparable with the results of the previous year quarter and nine months ended December 31, 2007. Earning per share in item 18 A & B is calculated considering the allotment to be made as per the scheme.
- [4] During the quarter, the company has acquired 100 % shareholding of Etna Biotech S.R.L., Italy through its wholly owned subsidiary (w.o.s.) - Zydus International Private Limited, Ireland (ZIPL)
- [5] During the quarter, Zydus Pharma USA, Inc has redeemed 30 % shares of the company and has now become a w.o.s. of ZIPL
- [6] During the quarter, Zydus Pharmaceuticals Inc., Japan was merged with Nippon Universal Pharmaceuticals Co. Limited, Japan.
- [7] The Change in investments during the quarter is as under :
[A] Zydus BSV Pharma Pvt. Ltd. [Additional Investments] Rs. 125 Lacs
[B] M/s. Zydus Healthcare [A partnership firm] [Additional Inv Rs. 755 Lacs
- [8] The status of investor complaints :
Pending at the beginning of the quarter - NIL, received and disposed off during the quarter - 22 - pending at the end of the quarter - NIL.
- [9] The Company has one segment of activity viz. " Pharmaceuticals ".

By Order of the Board,
For Cadila Healthcare Limited,

Pankaj R. Patel
Chairman & Managing Director

Ahmedabad, January 27, 2009